Skip to content

Establishment of Interstitial Lung Disease Organoids and Exploration of Biological Mechanisms

Establishment of Interstitial Lung Disease Organoids and Exploration of Biological Mechanisms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121900
Enrollment
Unknown
Registered
2026-04-07
Start date
2026-04-10
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease

Interventions

ILD Patient-Derived Organoid (PDO) Group:None

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged = 18 years, regardless of gender. 2.Understand the study procedures and methods, participate voluntarily, and sign the written informed consent form. 3.Patients with suspected ILD based on HRCT or thin-section CT requiring hospitalization for definitive diagnosis, or patients with a confirmed diagnosis of IPF or CTD-ILD. 4.No contraindications to bronchoscopy, and assessed as able to tolerate the procedure based on cardiopulmonary function.

Exclusion criteria

Exclusion criteria: 1.History of any significant medical condition which, in the opinion of the investigator, may adversely affect participation. 2.Female subjects who are pregnant or lactating. 3.Hepatitis B surface antigen positive or hepatitis B core antibody positive with HBV DNA =2000 IU/mL; hepatitis C antibody positive with HCV RNA =1000 IU/mL; human immunodeficiency virus antibody positive or a history of acquired immunodeficiency syndrome. 4.Patients with active respiratory tract infection, AECOPD, asthma, or other acute or uncontrolled cardiopulmonary diseases. 5.Presence of any other contraindications to bronchoscopy. 6.Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or ?-glutamyl transferase (GGT) exceeding the Upper Limit of Normal (ULN), or total bilirubin exceeding the ULN at the screening/baseline visit. 7.Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
Organoid Establishment Success Rate;Biological Differences Among ILD Subtype Organoids;

Secondary

MeasureTime frame
Identification of Disease-Associated Biomarkers;Scale of ILD Organoid Biobank Establishment;Accuracy of Drug Response Prediction;

Countries

China

Contacts

Public ContactQu jieming

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

qjm11865@rjh.com.cn+86 21 5466 1789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026